BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12235519)

  • 21. Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival.
    Gorak E; Geller N; Srinivasan R; Espinoza-Delgado I; Donohue T; Barrett AJ; Suffredini A; Childs R
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):542-50. PubMed ID: 15983554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
    Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children.
    González-Vicent M; Madero L; Sevilla J; Ramirez M; Díaz MA
    Bone Marrow Transplant; 2004 Dec; 34(12):1077-81. PubMed ID: 15516942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation.
    Lee CK; Gingrich RD; Hohl RJ; Ajram KA
    Bone Marrow Transplant; 1995 Jul; 16(1):175-82. PubMed ID: 7581119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progenitor content of autologous grafts: mobilized bone marrow vs mobilized blood.
    Dahl E; Burroughs J; DeFor T; Verfaillie C; Weisdorf D
    Bone Marrow Transplant; 2003 Sep; 32(6):575-80. PubMed ID: 12953129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
    Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed introduction of G-CSF after chemotherapy does not affect peripheral blood stem cell yield and engraftment kinetics in children with high-risk malignancies: retrospective study of 45 cases.
    Dolgopolov I; Andreeva L; Yankelevich M; Mscheidze D; Siegel S; Mentkevich G
    Am J Hematol; 2003 Aug; 73(4):225-9. PubMed ID: 12879423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
    Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
    Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.
    Oran B; Malek K; Sanchorawala V; Wright DG; Quillen K; Finn KT; La Valley M; Skinner M; Seldin DC
    Bone Marrow Transplant; 2005 Mar; 35(6):567-75. PubMed ID: 15665842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
    J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mobilization of peripheral blood stem cells for autologous transplantation patients with hematological malignancies: Influence of disease, mobilization method, age and sex.
    Zhang C; Chen X; Zhang X; Gao L; Kong P; Wang Q; Peng X; Liu H
    Transfus Apher Sci; 2008 Aug; 39(1):21-8. PubMed ID: 18599353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
    Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peri-engraftment syndrome in allogeneic hematopoietic SCT.
    Hong KT; Kang HJ; Kim NH; Kim MS; Lee JW; Kim H; Park KD; Shin HY; Ahn HS
    Bone Marrow Transplant; 2013 Apr; 48(4):523-8. PubMed ID: 23000648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
    Kasow KA; Sims-Poston L; Eldridge P; Hale GA
    Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
    Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
    Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD34+ cell responsiveness to stromal cell-derived factor-1alpha underlies rate of engraftment after peripheral blood stem cell transplantation.
    Marquez-Curtis LA; Turner AR; Larratt LM; Letcher B; Lee SF; Janowska-Wieczorek A
    Transfusion; 2009 Jan; 49(1):161-9. PubMed ID: 18954402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.
    Broers AE; van der Holt B; Haze S; Braakman E; Gratama JW; Löwenberg B; Cornelissen JJ
    Exp Hematol; 2005 Aug; 33(8):912-9. PubMed ID: 16038784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.